NeedyMeds is a 501(c)(3) national non-profit information source that connects people to programs that will help them afford their medications and other healthcare costs.
read more →
Another oral medication for people with type 1 diabetes recently struck out with the FDA, but approvals in Europe and Japan lead us to believe that the game isn’t yet over here in the states.
read more →
Injections are now optional for Ozemic…the FDA recently approved an oral form of Ozempic called Rybelsus, which is the first GLP-RA of its kind for people with type 2 diabetes.
read more →
Anytime your doctors prescribe a new drug for you, there are important things you need to share to ensure you get a prescription that will work safely and effectively.
read more →
Jeremy Pettus explains the pros and cons of SGLT2s for people with type 1, and offers advice on how to try them safely and smartly.
read more →
SGLT2s are currently only approved for use in the U.S. for type 2 diabetes, but a lot of people with type 1 are taking them off label with positive results.
read more →
If your diabetes doctor thinks you should start insulin, it doesn’t mean you aren’t managing your condition well. You probably need to start insulin because your pancreas is failing, not you.
read more →
Did you know only 20% of people with diabetes have all three common conditions under control: A1c, blood pressure and cholesterol? One of the big reasons is medication adherence.
read more →
The newest classes of diabetes meds to treat type 2 are pulling more than double duty, helping to better control blood sugars, protect the heart, lower body weight and prevent chronic kidney disease.
read more →
SGLT-2 Inhibitors including Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin) and Steglatro (ertugliflizin), are the newest class of oral medications for the treatment of type 2 diabetes. They’re generally well tolerated and associated with significant weight loss compared with other type 2 oral meds, but there are still precautions to consider.
read more →
